Breast cancer · 28 regimens
Cost vs Efficacy · 14 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
T-DM1 and ET Variant #01 | ER|ERBB2 | R 41 405 | 21d | — | — | — | — | — |
Trastuzumab emtansine monotherapy Variant #01 | ER|ERBB2 | R 41 405 | 21d | ~7.4 mo | ~29.9 mo | ~11 | ~R 455 454 PFS proxy · indirect | 7 |
Carboplatin and nab-Paclitaxel (CnP) Variant #01 | TNBC | R 38 912 | 21d | ~5.7 mo | ~13.9 mo | ~9 | ~R 350 208 PFS proxy · indirect | 11 |
Cyclophosphamide and Epirubicin (EC) and Bevacizumab Variant #01 | TNBC | R 30 701 | 21d | ~9.2 mo | — | ~14 | ~R 429 809 PFS proxy · indirect | 1 |
Docetaxel and Bevacizumab Variant #01 | TNBC | R 30 693 | 21d | ~8.2 mo | — | ~12 | ~R 368 311 PFS proxy · indirect | 4 |
Cisplatin and Bevacizumab Variant #01 | TNBC | R 28 998 | 21d | — | — | — | — | — |
Trastuzumab and ET Variant #01 | ER|ERBB2 | R 10 438 | 21d | — | — | — | — | — |
Dose-dense Cyclophosphamide and Doxorubicin (ddAC) N/A - secondary systemic drug | — | R 6 111 | 14d | — | — | — | — | 1 |
Dose-dense Cyclophosphamide and Doxorubicin (ddAC) N/A - secondary systemic drug | TNBC | R 6 111 | 14d | — | — | — | — | 1 |
iddEPC Variant #01 | — | R 5 301 | 14d | — | — | — | — | 1 |
Carboplatin and Paclitaxel (CP) Variant #38 | TNBC | R 5 031 | 21d | ~12.6 mo | ~28.2 mo | ~19 | ~R 95 583 PFS proxy · indirect | 2 |
EDC Variant #01 | — | R 4 688 | 21d | — | — | — | — | — |
DI EC Variant #01 | — | R 4 216 | 21d | — | — | — | — | — |
Docetaxel and Epirubicin (DE) Variant #01 | — | R 3 701 | 21d | — | — | — | — | — |
Carboplatin and Docetaxel (DCb) Variant #01 | TNBC | R 3 300 | 21d | ~4.7 mo | ~22.3 mo | ~7 | ~R 23 101 PFS proxy · indirect | 4 |
Epirubicin and Paclitaxel (EP) Variant #01 | — | R 3 172 | 21d | — | — | — | — | 1 |
Capecitabine and Docetaxel (TX) Variant #01 | — | R 3 056 | 21d | ~8.4 mo | ~14.5 mo | ~13 | ~R 39 725 PFS proxy · indirect | 3 |
TAC (Docetaxel) Variant #01 | — | R 2 667 | 21d | — | — | — | — | 2 |
Epirubicin monotherapy Variant #01 | — | R 2 611 | 21d | ~8.2 mo | ~19.1 mo | ~12 | ~R 31 334 PFS proxy · indirect | 1 |
Dose-dense Docetaxel and Doxorubicin (ddAT) Variant #01 | — | R 2 548 | 14d | — | — | — | — | — |
FEC Variant #01 | — | R 2 364 | 21d | — | — | — | — | 1 |
Paclitaxel monotherapy Variant #46 | — | R 2 220 | 28d | ~6.4 mo | ~16.8 mo | ~7 | ~R 15 537 PFS proxy · indirect | 28 |
Paclitaxel monotherapy Variant #46 | TNBC | R 2 220 | 28d | ~6.4 mo | ~16.8 mo | ~7 | ~R 15 537 PFS proxy · indirect | 28 |
PET Variant #01 | — | R 2 070 | 7d | — | — | — | — | — |
FAC Variant #01 | — | R 1 045 | 28d | ~8.0 mo | ~17.3 mo | ~9 | ~R 9 409 PFS proxy · indirect | 4 |
Cyclophosphamide and Doxorubicin (AC) Variant #01 | TNBC | R 718 | 21d | ~8.0 mo | ~20.3 mo | ~12 | ~R 8 611 PFS proxy · indirect | 2 |
Cyclophosphamide and Doxorubicin (AC) Variant #01 | — | R 718 | 21d | ~8.0 mo | ~20.3 mo | ~12 | ~R 8 611 PFS proxy · indirect | 2 |
Cisplatin monotherapy Variant #16 | TNBC | R 650 | 28d | ~2.1 mo | ~8.7 mo | ~3 | ~R 1 950 PFS proxy · indirect | 8 |
28 of 28 regimens shown